retatrutide vs semaglutide retatrutide vs semaglutide

Retatrutide vs Semaglutide: How Do They Compare?

Retatrutide vs semaglutide now has a direct answer for one group of people. In October 2026, Lilly reported the first head-to-head phase 3 trial of the two. In adults with type 2 diabetes, retatrutide lowered blood sugar more and produced about twice the weight loss of semaglutide after 80 weeks. These are early topline figures from the drug’s maker, they are not yet published in a journal, and retatrutide is still in trials.

The sections below explain how the two work, what the trials found, and what is still unknown.

Key takeaways

  • Retatrutide acts on three hormone signals. Semaglutide acts on one.
  • In one head-to-head trial, retatrutide beat semaglutide on blood sugar and weight loss at 80 weeks.
  • That trial was open-label, only included adults with type 2 diabetes, and is not yet peer reviewed.
  • Stomach side effects were similar. Skin tingling was reported more often with retatrutide.

Retatrutide vs Semaglutide at a Glance

SemaglutideRetatrutide
Hormone targetsGLP-1GIP, GLP-1 and glucagon
Brand namesOzempic, WegovyNone, still an investigational drug
Made byNovo NordiskEli Lilly
How long studiedMany years, many large trialsPhase 2 and several phase 3 trials
Head-to-head resultComparatorGreater A1C and weight loss in one trial

What Is Semaglutide?

Semaglutide is a lab-made copy of GLP-1, a gut hormone your body releases after you eat. GLP-1 tells the brain you are full, slows how fast the stomach empties, and helps the pancreas release insulin. A compound that switches on the GLP-1 receptor is called a GLP-1 agonist. An agonist is simply something that turns a receptor on.

Semaglutide is the active ingredient in Ozempic and Wegovy. Trials of the two used different doses. For how it stacks up against another dual-hormone drug, see tirzepatide compared with semaglutide.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injection made by Eli Lilly. People call it “reta” for short, and sometimes “GLP-3” online. That is a nickname, not the name of a real hormone.

It is a single molecule that acts on three receptors:

  • GIP: another gut hormone that helps release insulin and may affect how the body handles fat.
  • GLP-1: the same signal that semaglutide copies.
  • Glucagon: a hormone that raises blood sugar, and also makes the body use more energy.

How Do Their Hormone Targets Differ?

Think of three keys on one ring. Semaglutide turns one lock. Retatrutide turns three. The extra signals, especially glucagon, are thought to raise how much energy the body burns, on top of the appetite effect.

That is the theory behind the design. The trials test whether it shows up in results. Another peptide that adds a glucagon signal is covered in the guide to mazdutide, another glucagon-acting peptide.

What the Head-to-Head Trial Showed

The TRANSCEND-T2D-2 trial is the first phase 3 trial to put retatrutide against another incretin drug. An incretin drug is one that copies gut hormones such as GLP-1.

Measure at 80 weeksRetatrutide (two dose groups)Semaglutide 2 mg
A1C drop2.2%1.8%
Body weight loss19.5% to 20.9%9.4%

A1C is a blood test that shows your average blood sugar over about three months. A bigger drop means better control.

What the trial looked like:

  • It enrolled 1,298 adults with type 2 diabetes who were not controlled on metformin, with or without another diabetes pill.
  • Participants were randomly assigned to one of the retatrutide doses or to semaglutide.
  • It ran for 80 weeks.

Keep these limits in mind:

  • These are topline results, meaning a summary from Lilly. The full data are not yet published or peer reviewed.
  • The trial was open-label, so patients and doctors knew which drug was used.
  • It covered adults with type 2 diabetes only. Weight loss in this group is usually smaller than in people without diabetes, so the numbers do not apply to everyone.
  • 2 mg is the highest semaglutide dose used for diabetes. Obesity trials of semaglutide used 2.4 mg.

What Do Separate Trials Show?

Other trials add context, but they cannot be compared directly. The people, the length and the design all differ.

TrialStudy typeKey finding
TRIUMPH-2 (Lancet, 2026)Phase 3 vs placebo, 1,152 adults with obesity and type 2 diabetesThe highest retatrutide dose produced mean weight loss of 20.8%.
Retatrutide phase 2 (NEJM, 2023)Phase 2 trial, 338 adults, 48 weeksWeight loss of about 24% at the highest dose (verify).
STEP-1 (NEJM, 2021)Phase 3 vs placebo, 1,961 adults with obesity, 68 weeksAbout 15% weight loss with semaglutide 2.4 mg, against about 2% on placebo (verify).

Only TRANSCEND-T2D-2 compares the two drugs in the same trial. The rest are indirect.

Retatrutide vs Semaglutide Side Effects

Both drugs cause stomach side effects, which are common in this drug class. Here is what the head-to-head trial reported, as a percent of participants:

Side effectRetatrutide (two doses)Semaglutide 2 mg
Diarrhea28.3% and 32.7%26.4%
Nausea21.2% and 23.8%21.3%
Vomiting10.2% and 15.0%13.2%
Constipation14.2% and 13.1%19.8%
Skin tingling (dysesthesia)4.8% and 6.5%2.7%

Dysesthesia is an odd or unpleasant skin feeling, such as tingling or sensitivity. Stomach side effects were similar between the drugs. The main gap was dysesthesia, which was reported more often with retatrutide.

In earlier studies, side effects tended to rise with dose, and the doses tested in trials differ between studies.

Is Retatrutide Better Than Semaglutide?

On two measures in one trial, yes. Retatrutide lowered A1C more and produced more weight loss. “Better” still has limits:

  • There is only one direct comparison so far, in people with type 2 diabetes.
  • The data are not peer reviewed yet.
  • Semaglutide has been studied for much longer, so its long-term record is deeper.
  • Lilly is also running a head-to-head trial of retatrutide against tirzepatide, which has not reported.

What Is Still Unknown?

  • How the published version of the data compares with the topline summary
  • How the two drugs compare in people without diabetes
  • Long-term safety of retatrutide
  • How retatrutide performs against tirzepatide

Researchers who study retatrutide in lab settings usually source compounds from trusted platforms such as PeptidePro and ask for a certificate of analysis, or COA. A COA is a lab report that shows what is in the vial and how pure it is.

The wider question of peptides and weight loss safety depends on the compound, and retatrutide has far less long-term data than older drugs.

FAQs

Is retatrutide stronger than semaglutide?

In the first head-to-head trial, in adults with type 2 diabetes, retatrutide lowered A1C by 2.2% against 1.8% and body weight by 19.5% to 20.9% against 9.4% after 80 weeks. The results are topline and not yet peer reviewed.

Is retatrutide the same as Ozempic?

No. Ozempic contains semaglutide, which acts on one hormone receptor, GLP-1. Retatrutide acts on three: GIP, GLP-1 and glucagon. They are made by different companies, and retatrutide is still an investigational drug in trials.

Does retatrutide cause more side effects than semaglutide?

Stomach side effects such as nausea and diarrhea were similar in the head-to-head trial. Skin tingling, called dysesthesia, was reported more often with retatrutide, at 4.8% and 6.5% against 2.7% with semaglutide.

What is A1C?

A1C is a blood test that shows average blood sugar over about three months. It is used to track diabetes control. In the head-to-head trial, retatrutide lowered A1C by 2.2% and semaglutide by 1.8%.

Why is retatrutide called a triple agonist?

An agonist is a compound that switches on a receptor. Retatrutide switches on three: GIP, GLP-1 and glucagon. Semaglutide switches on only GLP-1. That is why retatrutide is called a triple agonist and semaglutide a single agonist.

This content is for educational and research purposes only. The compounds discussed are not intended for human consumption. Nothing here is medical advice. For any peptide use, readers should consult an expert who can advise what works best for them.